Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study
Marina Talamonti, Marco Galluzzo, Andrea Chiricozzi, Pietro Quaglino, Gabriella Fabbrocini, Paolo Gisondi, Angelo Valerio Marzano, Concetta Potenza, Andrea Conti, Aurora Parodi, Stefano Piaserico, Federico Bardazzi, Giuseppe Argenziano, Franco Rongioletti, Luca Stingeni, Giuseppe Micali, Francesco Loconsole, Mariateresa Rossi, Maria Rita Bongiorno, Claudio Feliciani, Pietro Rubegni, Paolo Amerio, Maria Concetta Fargnoli, Paolo D. Pigatto, Paola Savoia, Steven Paul Nisticò, Sandra Giustini, Andrea Carugno, Serafinella Patrizia Cannavò, Giulia Rech, Francesca Prignano, Annamaria Offidani, M. Lombardo, Iris Zalaudek, Luca Bianchi, Ketty Peris, for the PSO-BIO-COVID study group
Abstract
: The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen 'cytokine storm' of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.